Literature DB >> 23522884

Durable erythroid response after discontinuation of epoetin-alpha: an unexpected outcome in a patient with myelodysplastic syndrome.

Pasquale Niscola1, Marco Giovannini1, Andrea Tendas1, Laura Scaramucci1, Alessio Perrotti1, Paolo De Fabritiis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23522884      PMCID： PMC3934225          DOI： 10.2450/2013.0232-12

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  5 in total

Review 1.  Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes.

Authors:  Valeria Santini
Journal:  Oncologist       Date:  2011

2.  Cytogenetic effects on cells derived from patients with myelodysplastic syndromes during treatment with hemopoietic growth factors.

Authors:  G Verhoef; H Van den Berghe; M Boogaerts
Journal:  Leukemia       Date:  1992-08       Impact factor: 11.528

3.  rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples.

Authors:  Gian Matteo Rigolin; Matteo Della Porta; Renato Bigoni; Francesco Cavazzini; Maria Ciccone; Antonella Bardi; Antonio Cuneo; Gianluigi Castoldi
Journal:  Br J Haematol       Date:  2002-12       Impact factor: 6.998

4.  A hematological remission by clonal hematopoiesis after treatment with recombinant human granulocyte-macrophage colony-stimulating factor and erythropoietin in a patient with therapy-related myelodysplastic syndrome.

Authors:  M Bessho; Y Itoh; S Kataumi; N Kawai; A Matsuda; I Jinnai; M Saitoh; K Hirashima; M Minamihisamatsu
Journal:  Leuk Res       Date:  1992       Impact factor: 3.156

5.  In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells.

Authors:  Gian Matteo Rigolin; Matteo Della Porta; Maria Ciccone; Anna Maria Bugli; Letizia Zenone Bragotti; Endri Mauro; Chiara Fraulini; Antonella Russo Rossi; Antonella Bardi; Antonio Cuneo; Gianluigi Castoldi
Journal:  Br J Haematol       Date:  2004-08       Impact factor: 6.998
  5 in total
  1 in total

1.  Sustained resolution of anemia without any treatment after excessive therapeutic response to human recombinant erythropoietin in three patients with myelodysplastic syndromes.

Authors:  Pasquale Niscola; Andrea Tendas; Marco Giovannini; Laura Scaramucci; Luca Cupelli; Gianfranco Catalano; Alessio Perrotti; Paolo de Fabritiis
Journal:  Support Care Cancer       Date:  2013-04-21       Impact factor: 3.603
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.